Cabaletta Bio (CABA) Competitors $4.13 +0.31 (+8.12%) (As of 12/2/2024 06:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CABA vs. TRDA, TECX, ANAB, DNTH, ORIC, ABUS, TRML, ESPR, GLUE, and PHVSShould you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Entrada Therapeutics (TRDA), Tectonic Therapeutic (TECX), AnaptysBio (ANAB), Dianthus Therapeutics (DNTH), ORIC Pharmaceuticals (ORIC), Arbutus Biopharma (ABUS), Tourmaline Bio (TRML), Esperion Therapeutics (ESPR), Monte Rosa Therapeutics (GLUE), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry. Cabaletta Bio vs. Entrada Therapeutics Tectonic Therapeutic AnaptysBio Dianthus Therapeutics ORIC Pharmaceuticals Arbutus Biopharma Tourmaline Bio Esperion Therapeutics Monte Rosa Therapeutics Pharvaris Entrada Therapeutics (NASDAQ:TRDA) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings. Is TRDA or CABA more profitable? Entrada Therapeutics has a net margin of 25.53% compared to Cabaletta Bio's net margin of 0.00%. Entrada Therapeutics' return on equity of 16.11% beat Cabaletta Bio's return on equity.Company Net Margins Return on Equity Return on Assets Entrada Therapeutics25.53% 16.11% 10.39% Cabaletta Bio N/A -50.10%-45.49% Which has more risk and volatility, TRDA or CABA? Entrada Therapeutics has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 2.42, meaning that its stock price is 142% more volatile than the S&P 500. Do insiders & institutionals have more ownership in TRDA or CABA? 86.4% of Entrada Therapeutics shares are owned by institutional investors. 7.6% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 9.9% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to TRDA or CABA? In the previous week, Cabaletta Bio had 9 more articles in the media than Entrada Therapeutics. MarketBeat recorded 11 mentions for Cabaletta Bio and 2 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.71 beat Cabaletta Bio's score of 0.65 indicating that Entrada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cabaletta Bio 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, TRDA or CABA? Entrada Therapeutics has higher revenue and earnings than Cabaletta Bio. Cabaletta Bio is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntrada Therapeutics$129.01M5.89-$6.68M$1.5912.78Cabaletta BioN/AN/A-$67.68M-$2.15-1.92 Do analysts rate TRDA or CABA? Entrada Therapeutics currently has a consensus price target of $24.00, suggesting a potential upside of 18.11%. Cabaletta Bio has a consensus price target of $26.25, suggesting a potential upside of 535.59%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts clearly believe Cabaletta Bio is more favorable than Entrada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Cabaletta Bio 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Does the MarketBeat Community believe in TRDA or CABA? Cabaletta Bio received 73 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 80.00% of users gave Entrada Therapeutics an outperform vote while only 72.95% of users gave Cabaletta Bio an outperform vote. CompanyUnderperformOutperformEntrada TherapeuticsOutperform Votes1680.00% Underperform Votes420.00% Cabaletta BioOutperform Votes8972.95% Underperform Votes3327.05% SummaryEntrada Therapeutics beats Cabaletta Bio on 10 of the 18 factors compared between the two stocks. Ad WealthPressIs the Trump/Musk duo good for shares of TSLA?If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CABA vs. The Competition Export to ExcelMetricCabaletta BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$186.71M$3.10B$5.21B$8.91BDividend YieldN/A1.84%5.23%4.05%P/E Ratio-1.9215.5986.2513.46Price / SalesN/A314.321,470.3386.69Price / CashN/A175.8435.2835.09Price / Book0.753.774.935.04Net Income-$67.68M-$41.68M$117.66M$224.28M7 Day Performance70.66%6.36%2.86%1.98%1 Month Performance11.32%5.32%1.79%9.78%1 Year Performance-74.22%38.03%35.89%29.97% Cabaletta Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CABACabaletta Bio3.1046 of 5 stars$4.13+8.1%$26.25+535.6%-74.2%$186.71MN/A-1.9250Gap UpHigh Trading VolumeTRDAEntrada Therapeutics1.9834 of 5 stars$19.94+0.3%$24.00+20.4%+51.6%$746.16M$215.23M12.49110Positive NewsTECXTectonic Therapeutic3.2744 of 5 stars$49.770.0%$72.25+45.2%N/A$734.26MN/A-8.45120Short Interest ↑ANABAnaptysBio2.4126 of 5 stars$23.79-4.7%$54.64+129.7%+62.5%$723.93M$17.16M-3.82100Analyst DowngradeShort Interest ↑Gap DownDNTHDianthus Therapeutics1.9083 of 5 stars$24.12+0.5%$46.43+92.5%+128.0%$713.95M$2.83M-9.6080Short Interest ↑Positive NewsORICORIC Pharmaceuticals4.54 of 5 stars$9.81-0.9%$18.29+86.4%+23.0%$692.26MN/A-5.5080News CoveragePositive NewsABUSArbutus Biopharma2.9246 of 5 stars$3.50+1.2%$5.50+57.1%+70.4%$663.22M$18.14M-8.0573Short Interest ↓TRMLTourmaline Bio2.2297 of 5 stars$25.63-1.6%$65.00+153.6%+35.1%$657.15MN/A-9.1344Positive NewsESPREsperion Therapeutics4.0961 of 5 stars$3.31+18.2%$8.17+146.7%+115.3%$652.20M$116.33M-4.64240Short Interest ↓Analyst RevisionGLUEMonte Rosa Therapeutics2.4537 of 5 stars$10.53+1.6%$16.00+51.9%+227.6%$646.93M$14.98M-5.7190PHVSPharvaris2.1187 of 5 stars$20.19-7.8%$33.60+66.4%+3.0%$642.85MN/A-7.2930Gap Down Related Companies and Tools Related Companies TRDA Competitors TECX Competitors ANAB Competitors DNTH Competitors ORIC Competitors ABUS Competitors TRML Competitors ESPR Competitors GLUE Competitors PHVS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CABA) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CABA Stock Alerts